Zevra Therapeutics, Inc. (ZVRA)
AI stock analysis · as of Jun 10, 2026
Loading microstructure…
Zevra Therapeutics is a commercial-stage rare disease company whose investment case rests almost entirely on MIPLYFFA, its newly launched therapy for Niemann-Pick Type C (NPC), a U.S. diagnosed population of only ~300-350 patients. A $148.3M PRV sale in April 2025 transformed the balance sheet and, combined with MIPLYFFA's ramp (161 enrollments by YE25) and a freshly granted patent extending exclusivity to 2041, has driven the stock to multi-year highs. The core question: can MIPLYFFA's tiny but high-priced orphan market plus optionality from celiprolol (VEDS) and KP1077 justify the ~$800M market cap, or is the PRV windfall masking a fragile single-asset story facing direct competition from AQNEURSA?
valuationOptically cheap on trailing P/E 6.75 and forward P/E 9.49, but those metrics are distorted by the $148M PRV one-timer; EV/EBITDA of 47.75, P/S of 6.6, and PEG of 10.67 better reflect a fully-priced orphan-launch story with single-asset risk — fair to slightly expensive on a clean basis.
This analysis is from Jun 10, 2026. Want the latest on ZVRA, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · MIPLYFFA patent extension to 2041 dramatically widens the exclusivity moat for the company's only revenue driver, prompting analyst target hikes to $25-$34 (vs. $13.57 spot).
- · FY2025 revenue jumped to $106.5M (+775% YoY) with 84.5% gross margin and reported net income of $83.2M, demonstrating orphan-drug pricing economics — even adjusting for the PRV windfall, MIPLYFFA's launch trajectory is strong with 161 enrollments out of only 300-350 diagnosed patients (significant penetration headroom).
- · Balance sheet de-risked: $62.4M cash plus PRV proceeds, debt of only $63.2M, FCF nearly breakeven (-$2.4M) — funding runway extends through key clinical catalysts without near-term dilution pressure.
- · Pipeline optionality is meaningful: celiprolol Phase 3 in VEDS (~7,500 U.S. patients, no approved therapy, Breakthrough designation) and KP1077 in IH/narcolepsy (~237K patients) provide multiple shots on goal beyond the NPC base.
- · EU MIPLYFFA filing (July 2025) opens a ~1,100-patient European market plus a $4M XOMA milestone; AZSTARYS royalty stream offers up to $590M in milestone optionality.
- · Strong analyst conviction (9 analysts, strong_buy, mean target $26.33 = ~94% upside) combined with 10.2% short interest creates squeeze potential on positive catalysts.
Bear case
- · Extreme single-product, single-indication concentration: MIPLYFFA serves only 300-350 diagnosed U.S. patients; any reimbursement, access, or competitive setback is existential.
- · Direct competition from IntraBio's AQNEURSA (already approved for NPC) plus additional candidates (adrabetadex, cyclodextrin) in a microscopic patient pool threatens long-term pricing/share.
- · FY2025 profitability is heavily distorted by the $148.3M non-recurring PRV sale — headline P/E of 6.75 and 78% net margin are not representative of the underlying operating business, which has a history of recurring losses.
- · OLPRUVA is effectively a failed launch ($0.8M FY25 sales, S&M scaled back, strategic alternatives under review) while authorized RAVICTI generics intensify competition.
- · Active dispute with Commave/Corium over AZSTARYS royalties jeopardizes a key milestone/royalty stream the bull case relies on.
- · Celiprolol Phase 3 enrollment is slow (52/150 at YE25), the prior FDA CRL raises approval risk, and EV/EBITDA of 47.75 and PEG of 10.67 already price in substantial pipeline success.
Catalysts
- · Next earnings (May 6, 2026) — first clean look at MIPLYFFA quarterly run-rate post-launch and ex-PRV operating metrics.
- · EMA decision on MIPLYFFA MAA (filed July 2025) — unlocks European NPC market and $4M XOMA milestone.
- · Celiprolol Phase 3 enrollment progress updates and eventual readout — binary event in VEDS with no approved competition.
- · KP1077 Phase 3 initiation announcements for IH and narcolepsy expand the addressable opportunity narrative.
- · Resolution of the Commave/Corium AZSTARYS dispute — could materially affect royalty/milestone cash flows.
- · Short interest at 10.2% of float with 3.17 days to cover sets up squeeze potential on positive clinical or commercial surprises.
Key risks
- · Single-asset dependency on MIPLYFFA in an ultra-small diagnosed population with an approved competitor (AQNEURSA).
- · Underlying operating losses masked by one-time PRV proceeds; equity dilution risk returns if pipeline misses or MIPLYFFA stalls.
- · Celiprolol Phase 3 failure or further delay — prior FDA CRL is a meaningful precedent.
- · Sole-source CMO/API manufacturing risk could halt commercial supply.
- · OLPRUVA strategic outcome and potential impairment or write-down.
What to watch
- · May 6, 2026 earnings — MIPLYFFA quarterly enrollment additions and net revenue run-rate ex-PRV.
- · EMA action on MIPLYFFA MAA and any XOMA milestone trigger.
- · Celiprolol Phase 3 enrollment cadence updates (currently 52/150).
- · $13.80 52-week high as resistance; reaction to any AQNEURSA share-gain commentary on the downside.
- · AZSTARYS/Commave dispute resolution and any related royalty disclosures.
- · Short interest trends (10.2% of float) into clinical/commercial updates for squeeze setup.
Key metrics
Price target rationale
Base case ~$18 assumes ~7-8x P/S on a normalized $130-150M MIPLYFFA run-rate, modest credit for EU approval and pipeline optionality. Bull ($28) assumes EU approval, celiprolol Phase 3 success signals, and MIPLYFFA penetration toward 50%+ of diagnosed NPC patients — roughly in line with the street high end. Bear ($8.5) reflects AQNEURSA share loss, celiprolol delay/failure, and a return toward cash-plus-modest-royalty valuation.
On Wall Street's view (mixed): The $26 consensus target reasonably reflects MIPLYFFA's exclusivity-to-2041 moat and pipeline optionality, but it appears to underweight competition from AQNEURSA and the distortion from the PRV in headline financials. A target in the high-teens to low-$20s feels more defensible than the $26-$34 street range.
Latest filing (10-K)
Zevra is a one-product rare disease story riding MIPLYFFA's early commercial launch into a tiny NPC patient pool, bankrolled by a $148M PRV windfall, with a binary celiprolol Phase 3 and a struggling OLPRUVA drag weighing on the narrative.
Zevra Therapeutics is a commercial-stage rare disease company that generates revenue primarily from U.S. sales of MIPLYFFA (arimoclomol) for Niemann-Pick disease type C and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders, plus royalties and milestones from its partnered ADHD drug AZSTARYS. The company also received $148.3 million in net proceeds in April 2025 from selling a rare pediatric disease Priority Review Voucher it obtained upon MIPLYFFA's FDA approval in September 2024. It is advancing a Phase 3 pipeline candidate, celiprolol for vascular Ehlers-Danlos syndrome, and a Phase 3-ready asset, KP1077 for idiopathic hypersomnia.
What the news says · bullish
The dominant storyline is Zevra Therapeutics filing a new patent for MIPLYFFA that extends exclusivity to 2041, which has acted as a major catalyst for the stock hitting multi-year highs. Multiple analysts — Guggenheim, Cantor Fitzgerald, BTIG, Citizens, and H.C. Wainwright — have raised price targets ranging from $25 to $34, with at least one analyst calling the stock 'way undervalued' with 117% upside. The stock surged ~13% on the news and reached its highest levels in nearly five years, reflecting strong market conviction around the extended competitive moat for its sole approved drug. A minor governance note — shareholders voted to keep a classified board structure — adds a modest risk consideration but is clearly overshadowed by the patent catalyst. Coverage is reasonably robust and consistent, lending credibility to the bullish read.
This analysis is from Jun 10, 2026. Markets move. Get the current read on ZVRA and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.